Highlights of the Program
2 days business program:
Learn from real-world case studies by industry leaders.
SHOWCASING INNOVATION:
Discover the latest technology and techniques from across the industry.
leaders talk:
Hear from top-level experts about how to stay ahead in a fast-changing industry.
MULTIPLE STREAMS:
A business program that is multi-disciplinary, giving you a broad view of the industry.
SMART TECHNOLOGIES:
Explore the latest smart and AI-driven solutions, and see how they can be used in your business.
roundtable discussion:
Join talks with industry peers. Share ideas, make connections, and find new partners.
Program
Day 1 :
WEDNESDAY, 2 SEPTEMBER, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:25
IP STRATEGY AND PATENT PROTECTION FOR DRUG DELIVERY TECHNOLOGIES
Balvinder Matharu
HGF Limited
- Protecting overall product exclusivity by strengthening delivery and formulation IP positions
- Repurposing existing molecules through delivery innovation while managing patent strategy
- Reviewing freedom-to-operate risks across oral, long-acting and targeted platforms
09:25 - 09:30
Q&A SESSION ON IP STRATEGY FOR DRUG DELIVERY
09:30 - 09:55
EXOSOME-BASED DRUG DELIVERY: OPPORTUNITIES IN ENABLING PERSONALIZED THERAPIES FOR BRAIN DISORDERS
Luís Valente
iLoF
- Addressing challenges in developing brain-targeted personalized drug therapies
- Exploring exosomes as natural carriers for CNS-targeted delivery strategies
- Advancing engineered exosomes for precise delivery in neurological disorders
09:55 - 10:00
Q&A SESSION ON EXOSOMES FOR BRAIN-TARGETED THERAPEUTICS
10:00 - 10:25
PATIENT CENTRIC DESIGN FOR AUTOINJECTORS WITH LONGER INJECTION DURATIONS
Tom Lever
PA Consulting
- Considering how larger volumes, higher viscosity and slower rates extend autoinjector use times
- Reframing autoinjector design around comfort, usability and confidence during longer injections
- Adapting patient-centric features to support control, adherence and acceptance with longer dosing
10:25 - 10:30
Q&A SESSION ON PATIENT-CENTRIC AUTOINJECTOR DESIGN
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON EUROPEAN DRUG DELIVERY SUMMIT
11:30 - 11:55
ISO 10993-17:2023 IN COMBINATION PRODUCTS – HOW TO PERFORM TOXICOLOGICAL RISK ASSESSMENTS AND EXTRACTABLES/LEACHABLES EVALUATIONS THAT WITHSTAND BOTH NOTIFIED BODY AND EMA REVIEW
Petr Braťka
Czech Metrology Institute
- Interpreting ISO 10993-17 updates including TSLs and revised exposure assessment principles
- Connecting ISO 10993-18, Module 3 and hazard assessment into one risk-based narrative
- Avoiding common E/L deficiencies through realistic dose, kinetics and degradation assumptions
11:55 - 12:00
Q&A SESSION ON ISO 10993-17:2023 IN COMBINATION PRODUCTS
12:00 - 12:25
VYXEOS AND LIPOSOMAL DRUG DELIVERY: TRANSLATING FORMULATION INNOVATION INTO HAEMATOLOGICAL CLINICAL OUTCOMES
Barbara Siha
The London Clinic
- Demonstrating CPX-351 as a fixed-ratio liposomal platform with proven impact in AML
- Contrasting liposomes with ADCs, biologics and targeted agents across delivery and toxicity
- Translating formulation innovation into practice through preparation and toxicity management
- Anticipating hybrid and personalised delivery strategies that could reshape haematology care
12:25 - 12:30
Q&A SESSION ON LIPOSOMAL DELIVERY IN HAEMATOLOGY
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE EUROPEAN DRUG DELIVERY SUMMIT
13:30 - 14:00
PANEL DISCUSSION ON EUROPEAN DRUG DELIVERY SUMMIT
14:00 - 14:25
IMPROVING OUTCOMES THROUGH TARGETED INTERVENTION: MODERN STRATEGIES FOR LOCO-REGIONAL CANCER THERAPY
Helena Kelly
Royal College of Surgeons in Ireland -RCSI
- Advancing catheter, embolic and image-guided systems for high-dose local tumour therapy
- Integrating formulation factors such as viscosity and release kinetics to improve tumour penetration
- Exploring device-enabled delivery to overcome tumour barriers and personalise solid tumour care
14:25 - 14:30
Q&A SESSION ON DEVICE-ENABLED LOCO-REGIONAL THERAPY
14:30 - 14:55
ON-BODY INJECTORS & THE 2 ML MYTH: HOW SUBCUTANEOUS VOLUME MISCONCEPTIONS ARE CONSTRAINING DRUG DELIVERY AND DEVELOPMENT
Mehul Desai
Enable Injections, Inc.
- Identifying how subcutaneous volume myths have shaped high-dose development choices
- Analysing nurse, pharmacist and patient surveys on challenges with large-volume injections
- Evaluating on-body injectors to ease administration and de-risk delivery development
14:55 - 15:00
Q&A SESSION ON SUBCUTANEOUS ON-BODY INJECTORS
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:45
PROBING LIPID ORDER IN LNPs FOR RNA DELIVERY WITH LAURDAN SPECTROSCOPY
Katharina Beck
Universität Augsburg – Projekt LISO
- Investigating lipid structure in RNA LNPs using temperature-sensitive fluorescence dyes
- Quantifying lipid order with Laurdan to assess nanoparticle stability and membrane density
- Identifying correlations between lipid order, efficacy, and storage resilience in RNA carriers
15:45 - 15:50
Q&A SESSION ON LNP STRUCTURE, STABILITY AND RNA DELIVERY INSIGHTS
15:50 - 16:15
BREAKING SOLUBILITY BARRIERS: EVOLVING FROM ASD/LIPID/MICRONISATION PLATFORMS TO SUPERCRITICAL FLUID AND DEEP EUTECTIC SOLVENT TECHNOLOGIES
Sandeep Kumar
Quotient Sciences
- Tracing why BCS II/IV and beyond-Ro5 APIs still need more advanced solubility platforms
- Harnessing SCF and DES systems to improve dissolution and prevent recrystallisation
- Pairing next-gen and conventional tools to expand developability for difficult molecules
16:15 - 16:20
Q&A SESSION ON NEXT-GEN SOLUBILITY ENABLING TECHNOLOGIES
16:20 - 16:45
UTAC: ENGINEERING A BISPECIFIC THAT CONVERTS CLINICAL ANTIBODIES INTO ORAL FORMULATIONS USING ACTIVE RETRO-TRANSCYTOSIS
Maurits Kleijnen
Intract Pharma Ltd.
- Designing UTAC bispecifics to ferry clinical antibodies from gut lumen into blood
- Co-formulating UTAC with clinical IgG to achieve high oral bioavailability in mice
- Presenting macaque pilot data supporting active retro-transcytosis for oral biologics
16:45 - 16:50
Q&A SESSION ON UTAC-ENABLED ORAL ANTIBODY DELIVERY
16:50 - 17:15
HIGH-RESOLUTION TARGET VALIDATION FOR DRUG DELIVERY USING SPATIAL CELL SORTING
Amos Lee
Meteor Biotech
- Enriching rare driver and responder cell states by spatial sorting from intact tissues
- Generating cell-state multi-omics datasets from selected cells to confirm targets and on-target signatures
- De-risking translation by turning insights into biomarkers and guidance on required cell reach
17:15 - 17:20
Q&A SESSION ON SPATIAL CELL SORTING FOR VALIDATION
17:20 - 17:45
EFFICIENT ENTERIC PELLET COATING WITH REDUCED AGGLOMERATION
Marek Lachmann
Biogrund
- Tackling enteric pellet coating where high loads, long runs and small pellets drive agglomeration
- Choosing coating blends that achieve gastric resistance with less material and fewer agglomerates
- Streamlining BIOGRUND coatings to cut processing and deliver gastric resistance with thinner films
17:45 - 17:50
Q&A SESSION ON ENTERIC PELLET COATING AND AGGLOMERATION
17:50 - 18:50
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, 3 SEPTEMBER, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:10
PANEL DISCUSSION ON EUROPEAN DRUG DELIVERY SUMMIT
09:10 - 09:35
A NOVEL TARGETED, INTRACELLULAR DELIVERY TECHNOLOGY FOR PROTEIN THERAPEUTICS
Marie McAvoy
NanoSyrinx
- Introducing nanosyringes for precise intracellular protein therapeutic delivery
- Unlocking new potential for drugging currently inaccessible intracellular targets
- Advancing synthetic biology to enable novel modalities for intracellular therapies
09:35 - 09:40
Q&A SESSION ON INTRACELLULAR DELIVERY FOR PROTEIN THERAPEUTICS
09:40 - 10:05
CAVEOLAE PUMPING ACROSS ENDOTHELIUM TO BOOST PRECISION DRUG DELIVERY, POTENCY AND EFFICACY
Jan Schnitzer
Proteogenomics Research Institute for Systems Medicine (PRISM)
- Examining endothelial barriers that limit targeting efficiency and heighten systemic toxicity
- Targeting caveolae to enable precision extravasation of therapeutics across endothelium
- Enhancing drug concentration and impact through active endothelial transport mechanisms
10:05 - 10:10
Q&A SESSION ON ENDOTHELIAL TARGETING FOR ENHANCED DRUG POTENCY
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
10:30 - 11:00
PANEL DISCUSSION ON EUROPEAN DRUG DELIVERY SUMMIT
11:00 - 11:25
FEASIBILITY ASSESSMENTS: PARTNERING EARLY TO MITIGATE COMBINATION PRODUCT DEVELOPMENT RISKS AND IMPROVE SPEED TO
Celine Wassaf
Becton Dickinson (BD)
- Identifying key risks in combination product and wearable injector development strategies
- Demonstrating how early feasibility assessments de-risk device and drug compatibility issues
- Highlighting case studies on data-driven collaboration to reduce time-to-market obstacles
11:25 - 11:30
Q&A SESSION ON EARLY PARTNERING TO DE-RISK COMBINATION PRODUCTS
11:30 - 11:55
UNLOCKING THE POTENTIAL OF INTRA-TISSUE DELIVERY FOR ADVANCED THERAPIES, PHARMACEUTICALS AND OTHER THERAPEUTIC PAYLOADS
Ricardo Baptista
SmartCella Holding AB
- Deploying catheter-based delivery for precise endovascular intra-tissue administration
- Targeting hard-to-reach tumours, tissues and organs while preserving vascular integrity
- Enabling repeatable image-guided local dosing with reduced systemic exposure for scale
11:55 - 12:00
Q&A SESSION ON INTRA-TISSUE DELIVERY
12:00 - 12:25
BEYOND THE FORMULATION: CLOSING THE ADOPTION GAP FOR NEXT-GEN DRUG DELIVERY SYSTEMS
Andreas Baier
Ergonomics Factory Group
- Diagnosing why approved delivery platforms can remain invisible in real-world clinical uptake
- Aligning clinical, R&D and commercial teams early to de-risk adoption and value evidence
- Applying stakeholder insight and interface engineering to meet regulator, payer and patient needs
12:25 - 12:30
Q&A SESSION ON CLOSING THE ADOPTION GAP FOR DEVICES
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE EUROPEAN DRUG DELIVERY SUMMIT
13:30 - 13:55
NANOFITINS FOR SELECTIVE AND ENHANCED DELIVERY OF NUCLEIC ACIDS
Olivier Kitten
Affilogic
- Engineering hyperstable protein scaffolds to target specific cell types for internalisation and BBB crossing
- Coupling Nanofitins with siRNAs to achieve efficient gene knockdown in targeted cells including the brain
- Boosting mRNA-encoded protein function hundredfold by conjugating Nanofitins with lipid nanoparticles
13:55 - 14:00
Q&A SESSION ON NANOFITIN-MEDIATED NUCLEIC ACID DELIVERY
14:00 - 14:25
A NEW APPROACH TO NOSE-TO-BRAIN DELIVERY – NOSEPLUG AS A SUSTAINED RELEASE CARRIER IN THE VESTIBULUM
Peter Åhnblad
Hogne AB
- Harnessing mucociliary motion to guide delivery with in-place vestibular device design
- Stimulating olfactory and trigeminal pathways to enhance brain-targeted uptake efficacy
- Controlling release kinetics for both immediate and sustained nose-to-brain distribution
14:25 - 14:30
Q&A SESSION ON NASAL DEVICES FOR SUSTAINED BRAIN DELIVERY
14:30 - 14:55
NANOTECHNOLOGIES FOR ADVANCED DRUG DELIVERY AND FUNCTIONAL SURFACE ENGINEERING IN PHARMACEUTICAL SYSTEMS
Beatrice Iaia
BioTitan Nanotechnology
- Translating nature-inspired material principles into nanostructured coatings for enhanced drug stability
- Releasing therapeutics in a controlled and targeted manner via engineered nanostructured interfaces
- Aligning surface engineering strategies with European green regulatory frameworks to cut chemical load
14:55 - 15:00
Q&A SESSION ON NANOTECHNOLOGY AND SURFACE ENGINEERING
15:00 - 15:15
FEEDBACK & RAFFLE DRAW
15:15 - 15:30
NETWORKING LUNCH
Become a Speaker & Join the Conversation
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.